Program
pemafibrate
Also written as “K-877”, “K-877 0.1 mg tablet” and “K-808 (Dose A)”.
Its studies are mostly in Liver Cirrhosis, Biliary · Hypercholesterolemia · Dyslipidemias · Hyperlipidemias · Non-alcoholic Fatty Liver Disease, led by Kowa.
Furthest: phase 4, since Jun 4, 202617 company-led studies, 1 open or runningNext primary completion: Jul 31, 2027 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kowa | 171 open or running | phase 4since Jun 4, 2026 | Oct 22, 2014 | Jul 31, 2027phase 4 · NCT07634484 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 22, 2014First studies: 5 phase 1 studies in HealthyFirst studyNCT02273986, NCT02276001, NCT02275988 and 2 more
- Jan 29, 2016Phase 1 study in HealthyNCT02719431 · 20 enrolled · United States
- Sep 15, 2016Phase 1 study in HealthyNCT02922465 · 20 enrolled · United States
- Feb 23, 2017Phase 3 study in DyslipidemiasNCT03071692 · 10,544 enrolled · United States, Argentina, Brazil and more
- Nov 9, 2017Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03350165 · 118 enrolled · Japan
- Sep 3, 2019Phase 2 study in DyslipidemiasNCT04079530 · 60 enrolled · Japan
- Jan 16, 2020Phase 1 study in HealthyNCT04237597 · 20 enrolled · United States
- Jan 29, 2021Phase 1 study in HealthyNCT04742218 · 18 enrolled · United States
- Jul 14, 2021Phase 3 study in HyperlipidemiasNCT04998981 · 353 enrolled · China
- Jun 20, 2023Phase 3 study in HypercholesterolemiaNCT05923281 · 71 enrolled · Japan
- Jan 22, 2024Phase 2 study in Liver Cirrhosis, BiliaryNCT06247735 · 46 enrolled · United States, Canada, Japan
- Jun 27, 2024Phase 1 study in Liver Cirrhosis, BiliaryNCT06525311 · 17 enrolled · United States, Japan
- Jun 4, 2026Phase 4 study in HypercholesterolemiaNCT07634484 · 120 planned · Japan
Ahead
- Jul 31, 2027Primary completion: phase 4 study in HypercholesterolemiaNCT07634484
TargetBeta
PPARA →read by rule
“Peroxisome proliferator-activated receptor alpha agonist”ChEMBL 37, by rule
Other programs on PPARA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| saroglitazarrule | Zydus Lifesciences | phase 4 | 19 |
| elifibranorrule | Genfit | phase 3 | 24 |
| seladelparrule | Gilead Sciences | phase 3 | 14 |
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
| Gemfibrozilrule | polaryx-therapeutics-inc | phase 3 | 8 |
| lanifibranor | inventiva-pharma | phase 3 | 6 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07634484Hypercholesterolemia · Japan | 4 | Recruiting | Jul 31, 2027 | 120 |
| NCT06525311Liver Cirrhosis, Biliary · United States, Japan | 1 | Completed | Mar 12, 2025 | 17 |
| NCT06247735Liver Cirrhosis, Biliary · United States, Canada, Japan | 2 | Completed | Jun 26, 2025 | 46 |
| NCT05923281Hypercholesterolemia · Japan | 3 | Completed | Aug 7, 2024 | 71 |
| NCT04998981Hyperlipidemias · China | 3 | Completed | Feb 2, 2023 | 353 |
| NCT04742218Healthy · United States | 1 | Completed | Apr 11, 2021 | 18 |
| NCT04237597Healthy · United States | 1 | Completed | Jan 31, 2020 | 20 |
| NCT04079530Dyslipidemias · Japan | 2 | Completed | Dec 24, 2019 | 60 |
| NCT03350165Non-alcoholic Fatty Liver Disease · Japan | 2 | Completed | Apr 3, 2019 | 118 |
| NCT03071692Dyslipidemias · United States, Argentina, Brazil and more | 3 | Terminated | Jul 27, 2022 | 10,544 |
| NCT02922465Healthy · United States | 1 | Completed | Oct 2016 | 20 |
| NCT02719431Healthy · United States | 1 | Completed | Feb 2016 | 20 |
| NCT02276001Healthy · United States | 1 | Completed | Jul 2014 | 20 |
| NCT02275988Healthy · United States | 1 | Completed | Aug 2014 | 20 |
| NCT02275975Healthy · United States | 1 | Completed | Aug 2014 | 20 |
| NCT02275962Healthy · United States | 1 | Completed | Oct 2014 | 20 |
| NCT02273986Healthy · United States | 1 | Completed | Sep 2014 | 20 |
How it is read
Names in the registry
- “K-877”, 11 entries
- “K-877 0.1 mg tablet”, 2 entries
- “K-808 (Dose A)”, 1 entry
- “K-808 (Dose B)”, 1 entry
- “Pemafibrate 0.2 mg/day”, 1 entry
Conditions, from the studies’ own filings
- Liver Cirrhosis, Biliary, 2 studies
- Hypercholesterolemia, 2 studies
- Dyslipidemias, 2 studies
- Hyperlipidemias, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.